Citius Oncology (CTOR) EBT (2023 - 2026)

Citius Oncology (CTOR) has reported EBT for 4 consecutive years, with -$9.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 76.88% year-over-year to -$9.0 million in Q2 2026; TTM through Jun 2026 was -$45.9 million, a 39.54% decrease from a year earlier, with the FY2025 full-year figure at -$23.7 million, down 15.22% from the prior year.
• EBT was -$9.0 million for Q2 2026 at Citius Oncology, up from -$26.8 million in the prior quarter.
• Over five years, EBT peaked at -$147922.0 in Q1 2023 and troughed at -$26.8 million in Q1 2026.
• A 4-year average of -$7.2 million and a median of -$5.3 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 6867.44% in 2024 and jumped 63.28% in 2025, its largest moves.
• Over 4 years, EBT stood at -$4.6 million in 2023, then slumped by 39.52% to -$6.4 million in 2024, then climbed by 17.59% to -$5.3 million in 2025, then slumped by 71.38% to -$9.0 million in 2026.
• The last three EBT figures came in at -$9.0 million (Q2 2026), -$26.8 million (Q1 2026), and -$5.3 million (Q4 2025), per Business Quant data.